HR Execs on the Move

CardioDX

www.cardiodx.com

 
The mission of Crescendo Bioscience, Inc. is to enable more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience is currently focused on rheumatoid arthritis (RA), a debilitating, chronic disease affecting over 1.5 million people in the United States and more than 2 million in Europe. Although there is no known cure for RA, multiple therapies are available, with widely differing levels of effectiveness and significant potential toxicities. Choosing the optimal treatment from among these therapeutic alternatives is a tremendous challenge. At Crescendo Bioscience, we are ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cardiodx.com
  • 600 Saginaw Drive
    Redwood City, CA USA 94063
  • Phone: 650.475.2788

Executives

Name Title Contact Details
Justin Schoenmoser
 Director Human Resources Profile
Justin Schoenmoser
 Director Human Resources Profile
Gwen Carscadden
 Human Resources Vice President Profile

Similar Companies

JVHL

JVHL is a Allen Park, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Educational and Diagnostic Services Inc

Educational and Diagnostic Services Inc is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Borg and Ide Imaging PC

Borg & Ide Imaging PC is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Durham Diagnostic Imaging

Durham Diagnostic Imaging is a Durham, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.